House Introduces New Drug Tracking Bill
On June 14, 2007 Rep. Dan Burton (R-IN) introduced a bill to the House that would mandate anti-counterfeiting technology in prescription drug packages, primarily highlighting RFID technology or "similar trace and track technologies that have an equivalent function." In addition to mandating an e-pedigree for the drug shipments, the drug packaging would also be required to have a feature that would visibly indicate if a drug package had been tampered with. The bill, H.R. 2716, charges the Secretary of Health and Human Services, which oversees the FDA, to implement this task.
H.R. 2716 also includes a Privacy Protection clause, which prohibits any personal information on the user of the prescription drug or the health care practitioner from being contained on the tag. Advertising would also not be allowed to be contained on or transmitted from the tag.
The bill has so far been referred to the House Committee on Energy and Commerce.
Continuing with the previous discussion on this blog about new pharma legislation, the debate in Congress over how best to utilize technology to address epedigree and anti-counterfeiting interests has now migrated to the House.
Those interested in the outcome of this debate -- whether RFID vendors, pharma manufacturers, wholesalers, retailers, etc -- the opportunity to influence the outcome is at hand.
Written By:gautam
On August 14, 2007 2:24 AM
H.R. 2716 also includes a Privacy Protection clause, which prohibits any personal information on the user of the prescription drug or the health care practitioner from being contained on the tag. Advertising would also not be allowed to be contained on or transmitted from the tag.
The bill has so far been referred to the House Committee on Energy and Commerce.
Continuing with the previous discussion on this blog about new pharma legislation, the debate in Congress over how best to utilize technology to address epedigree and anti-counterfeiting interests has now migrated to the House.
Those interested in the outcome of this debate -- whether RFID vendors, pharma manufacturers, wholesalers, retailers, etc -- the opportunity to influence the outcome is at hand.
I believe it will help in weeding out fake drugs from the market and save precious lives a s result!!